Search

Your search keyword '"C. Labeyrie"' showing total 74 results

Search Constraints

Start Over You searched for: Author "C. Labeyrie" Remove constraint Author: "C. Labeyrie"
74 results on '"C. Labeyrie"'

Search Results

3. Treating hereditary transthyretin amyloidosis: Present & future challenges

5. Actualités dans les neuropathies amyloïdes

7. Atteinte cérébelleuse d’origine auto-immune : à propos de deux cas avec hypermétabolisme cérébelleux

9. Urinary tract infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society

10. [Autologous hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyneuropathy]

11. Sarcoïdose médullaire mimant une myélopathie cervico-arthrosique : mauvais pronostic après chirurgie

12. New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions

13. Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society

14. Early detection of cardiac and skin amyloid deposits among asymptomatic carriers of hereditary pathogenic transthyretin mutation

15. Upper limb onset of hereditary transthyretin amyloidosis is common in non-endemic areas

16. SAT0429 How phenotype of the small fibre neuropathy (SFN) in primary sjÖgren syndrome (PSS) differs from others causes of small fibre neuropathy?

17. Improving Operation Safety of Multi Zone Single Trip Gravel Pack : Holistic Approach to Minimize Well Control Risk in Mahakam

18. Hydrogen Hypering at Tesca

19. General Properties of Kodak Plates Used in Astronomy

20. Nonamyloidogenic TTR gene variants c.76G>A and c.337-18G>C are not associated with idiopathic small-fiber neuropathy.

21. Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study.

22. Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.

23. Transthyretin amyloid polyneuropathy in France: A cross-sectional study with 413 patients and real-world tafamidis meglumine use (2009-2019).

24. Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis.

25. Clinical, paraclinical and outcome features of 166 patients with acute anti-GQ1b antibody syndrome.

26. Frequent detection of IFN-gamma -producing memory effector and effector T cells in patients with progressive multifocal leukoencephalopathy.

27. Detailed clinical, physiological and pathological phenotyping can impact access to disease-modifying treatments in ATTR carriers.

28. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.

30. Alemtuzumab-induced immune-mediated thrombotic thrombocytopenic purpura: A newly described drug-related autoimmune disease.

31. Hereditary transthyretin amyloidosis in middle-aged and elderly patients with idiopathic polyneuropathy: a nationwide prospective study.

32. French protocol for the diagnosis and management of hematopoietic stem cell transplantation in autoimmune diseases.

33. Red Flags for Chronic Inflammatory Demyelinating Polyradiculoneuropathy Associated with Sarcoidosis or Connective Tissue Diseases.

34. [Peripheral neuropathies during systemic diseases: Part II (vasculitis)].

35. [Peripheral neuropathies during systemic diseases: Part I (connective tissue diseases and granulomatosis)].

37. Strategy for genetic analysis in hereditary neuropathy.

38. Treating hereditary transthyretin amyloidosis: Present & future challenges.

39. Anti-disialosyl-immunoglobulin M chronic autoimmune neuropathies: a nationwide multicenter retrospective study.

40. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.

41. Amyloidosis from the patient perspective: the French daily impact of amyloidosis study.

42. Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis.

43. Neuropathies périphériques associées aux syndromes lymphoprolifératifs : spectre clinique et démarche diagnostique.

44. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.

45. Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae.

46. Determinants of therapeutic lag in multiple sclerosis.

47. Genotype-phenotype correlation in French patients with myelin protein zero gene-related inherited neuropathy.

48. [Autologous hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyneuropathy].

49. Inflammatory demyelinating polyneuropathies and lymphoma: clues to diagnosis and therapy.

50. The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies.

Catalog

Books, media, physical & digital resources